23andMe Holding (ME) and Mirador Therapeutics said Wednesday they have entered into a research partnership to combine the Mirador360 development engine and 23andMe's research database for target validation and precision medicine.
Financial terms weren't disclosed.
The collaboration is intended to identify new targets and develop new drugs to treat immunology and inflammation diseases, the companies said.
Price: 3.44, Change: +0.01, Percent Change: +0.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments